|
|
|
|
Albuferon Pulmonary Adverse Events
Human Genome Sciences Modifies Dosing in ACHIEVE Trials of Albuferon Rockville, Maryland - January 23, 2008 - Human Genome Sciences Inc.(Nasdaq: HGSI) announced today that it will modify the dosing in one arm of each of its ACHIEVE...
|
|
|
AASLD: Escitalopram Prophylaxis Shows Promise for HCV Treatment-Related Depression
SAN FRANCISCO, Nov.5 -- Patients with hepatitis C infection were significantly less likely to develop treatment-related depression when given prophylactic escitalopram (Lexapro), German investigators reported here. Prophylactic...
|
|
|
Human Genome Sciences Awaiting Crucial Albuferon Data
Recent headlines that Susquehanna analysts have downgraded their rating on Human Genome Sciences (HGSI) from positive to neutral, whilst negative for sentiment, may have initially appeared relatively innocuous given the tough financial...
|
|
|
Reportlinker: F. Hoffmann-La Roche Ltd. Company Profile Just Released: Reported Sales and
Hoffmann-La Roche Ltd.: PharmaVitae Profile http://www.reportlinker.com/p097346/F-Hoffmann-La-Roche-Ltd- PharmaVitae-Profile.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field.Remove...
|
|
|
Reportlinker: F. Hoffmann-La Roche Ltd. Company Profile Just Released: Reported Sales and Forecasts, Market Sh
NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.(Due to its length, this URL may need to be copied/pasted into your Internet...
|
|
|
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial wit
BRISBANE, Calif., Nov.10 /PRNewswire-FirstCall/ -- Roche (SWX:ROG - News), InterMune, Inc. (Nasdaq: ITMN - News) and Pharmasset (Nasdaq: VRUS - News) today announced that the first patients have been dosed in an innovative clinical...
|
|
|
Pharmasset to Present at Two Upcoming Investor Conferences
PRINCETON, N.J., Nov.10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS - News) announces management will present at the Rodman and Renshaw 10th Annual Global Investment Conference and the Lazard Capital Markets 5th Annual...
|
|
|
Vertex announces positive data at the annual AASLD meeting
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection l PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration l PROVE 2 final results...
|
|
|
Enzon Reports Solid Third Quarter 2008 Results
- Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced solid third quarter 2008 financial results. For the three months ended September 30, 2008, Enzon reported a net loss of $2.0 million or $0.05 on a diluted per-share basis, as...
|
|
|
Enzon Reports Solid Third Quarter 2008 Results
BRIDGEWATER, N.J., Nov.8, 2008--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced solid third quarter 2008 financial results. For the three months ended September 30, 2008, Enzon reported a net loss of $2.0...
|
|
|
Enzon Reports Solid Third Quarter 2008 Results
Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced solid third quarter 2008 financial results. For the three months ended September 30, 2008, Enzon reported a net loss of $2.0 million or $0.05 on a diluted per-share basis, as...
|
|
|
Roche: Study Shows Pegasys Effective In Hepatitis C Patients
ZURICH -(Dow Jones)- Swiss drugmaker Roche Holding AG (RHHBY) said Monday that a new, independently conducted study presented at the American Association for the Study of Liver Disease conference, AASLD, shows that PEGASYS ...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to...
|
|
|
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to...
|
|
|
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
BASEL, Switzerland, November 1 /PRNewswire/ -- A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to...
|
|
|
Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-t
- Three New Studies Presented at AASLD Demonstrate Efficacy and Safety of Extended Treatment in Non-Responders, Relapsers and Slow-Responders Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved...
|
|
|
Vertex Pharmaceuticals Highlights Progress with Hepatitis C and Cystic Fibrosis Programs and Reports Third Qua
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported recent clinical progress and consolidated financial results for the quarter ended September 30, 2008.'2008 has been a year of significant progress across all aspects of our...
|
|
|
Vertex Pharmaceuticals Highlights Progress with Hepatitis C and Cystic Fibrosis Programs and Reports Third Qua
-Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported recent clinical progress and consolidated financial results for the quarter ended September 30, 2008.2008 has been a year of significant progress across all aspects of our...
|
|
|
Committee For Medicinal Products For Human Use Post-Authorisation Summary Of Positive Opinion For Pegasys
International Nonproprietary Name (INN): peginterferon alfa-2a LONDON, Oct.23, 2008-On 23 October 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the...
|
|
|
Committee For Medicinal Products For Human Use Post-Authorisation Summary Of Positive Opinion For Pegasys
the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal product Pegasys.The Marketing Authorisation Holder for...
|
|
|
EU Panel Backs Wider Approval Of Merck's Erbitux
ZURICH -(Dow Jones)- The Committee for Medicinal Products for Human Use of the European Medicines Agency, an advisory panel to the EU drug watchdog adopted positive opinions for the following medicines: * Lunivia (eszopiclone), from Sepracor...
|
|
|
Roche HCV Drug R1626 Terminated
This was part of Roche earnings report over the internet today: 'Development of R1626, a polymerase inhibitor being investigated as a treatment for infection with hepatitis C virus (HCV), was terminated in the third quarter due to new and...
|
